RankAlpha logo
Back to Rankings

MRVI

Maravai LifesciencesD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The bull case is that Q1 was not just a one-time pop: TriLink base non-COVID revenue grew 15.4%, total TriLink revenue grew 65.1%, adjusted EBITDA turned positive at $20.3 million, free cash flow returned positive, and management raised both revenue and EBITDA guidance off the print. That combination supports a cleaner turnaround narrative than the prior filing-monitoring baseline.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.2.
What can break
A meaningful portion of Q1 upside came from $14.3 million of high-volume CleanCap orders for commercial COVID vaccine programs, which may not be a durable quarterly run rate. [#8-K-2026-05-07]
Momentum
96
Value
41
Sentiment
7
Setup hits (3d)
— · Net —
AI TargetsBase $4.30 · Bull $5.60 · Bear $3.10
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net —
Target $5.90
Why
Momentum96 · Δ7d +4.2
Value41 · Δ7d -0.1
Sentiment7 · Δ7d -12.9
So what
Weak posture. Prioritize risk control and patience.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendImproving
Δ7d
+4.2
Δ21d
+1.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
7
34% active weight
Current posture
7d trendSoftening
Δ7d
-12.9
Δ21d
-11.0
Why this grade

Composite grade D. Momentum 95.8 / Value 41.1 / Sentiment 6.6

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.87B
Beta
0.38
Shares Out
147.51M
P/E (TTM) · Derived
-14.0
P/S (TTM)
5.04
P/FCF (TTM) · Derived
-35.33
Rev YoY
+40.5%
EPS YoY
-87.8%
Gross Margin
+28.4%
Op Margin
-102.9%
Net Debt
$147.82M
Current Ratio
5.91
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology